Personalis
- Company typePublic
- Founded2011
- HeadquartersMenlo Park, United States
- Headcount251–500
- GTM typeB2B
- OfferingServices
What Personalis does
Personalis, Inc. (NASDAQ: PSNL) is a public precision oncology company founded in 2011 and headquartered in Fremont, California, that develops genome-scale diagnostic services and contract research offerings built around its NeXT Personal ultrasensitive molecular residual disease (MRD) testing platform. The core technology uses whole-genome sequencing to detect circulating tumor DNA (ctDNA) in blood plasma at a sensitivity of approximately 1 part per million while tracking up to approximately 1,800 patient-specific tumor mutations per patient, enabling recurrence detection a median of 5-9 months ahead of standard imaging and longitudinal monitoring of therapy resistance mutations such as ESR1 through its Real-Time Variant Tracker module. Supporting the MRD franchise is a broader NeXT Level solid tumor profiling stack (NeoantigenID, InfiltrateID, ImmunogenomicsID, RepertoireID) and the ImmunoID NeXT biopharma biomarker discovery platform, all processed through the company's on-site CAP-accredited clinical genomics laboratory.
The company monetizes through two primary streams: clinical diagnostic testing reimbursed by Medicare/MolDX for covered indications (breast cancer recurrence surveillance for Stage II-III patients, Stage I-III non-small cell lung cancer surveillance, immunotherapy monitoring for late-stage solid tumors, and breast cancer neoadjuvant therapy monitoring), and contract research and biopharma testing services including the Veterans Affairs Million Veteran Program and pharmaceutical collaborations such as the AstraZeneca Phase 3 LAURA trial. Customer segments span medical and surgical oncologists at comprehensive cancer centers, biopharmaceutical companies running oncology clinical trials, and Medicare-covered patients; commercial reach is extended through a strategic Tempus AI reference laboratory agreement that targets approximately 150,000 colorectal cancer patients annually. GTM combines direct enterprise field sales to oncologists and cancer centers with channel partnerships (Tempus AI), event-driven clinical evidence dissemination at ASCO, AACR, ESMO, and SABCS conferences, and peer-reviewed publications that anchor the reimbursement case for each new Medicare indication.
Personalis firmographics
Firmographics- Name
- Personalis
- Legal name
- Personalis, Inc.
- Website
- https://personalis.com
- Company type
- Public
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Ownership category
- akta.pro rank
Personalis industry classification
Industry- Product category
- Cancer Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG)
- akta.pro secondary industries
- Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling) (HLAAAMAK), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)
Keywords
Where Personalis is headquartered
LocationHeadquarters
- HQ city
- Menlo Park
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Personalis business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Clinical Diagnostic Testing: Clinical test revenue from NeXT Personal MRD tests performed on patient samples. Revenue grew 365% to $1.4 million following Medicare coverage approvals. Reimbursed through Medicare for covered indications including breast cancer and lung cancer surveillance.
- Pharmaceutical Testing Services: Contract testing services for pharmaceutical companies conducting clinical trials. Revenue declining due to wind-down of enterprise relationships and planned reduction in non-core revenue.
- VA MVP Program: Population sequencing services for the Veterans Affairs Million Veteran Program. Revenue reduced in recent periods as expected wind-down continues.
- Biopharma Partnerships: Collaborative research and testing services with biopharma companies including AstraZeneca for clinical trial support and companion diagnostic development.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Usage-based | Pay-as-you-go | Medicare-reimbursed clinical testing |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels7 records
Personalis product offering
Product offeringCore offering
Personalis fundamentally sells clinical diagnostic testing services and products centered on the NeXT Personal ultrasensitive minimal residual disease (MRD) test, which uses whole-genome sequencing to detect circulating tumor DNA down to ~1 part per million for cancer recurrence detection. The company also offers the NeXT Dx tissue and liquid biopsy assay for solid tumor profiling, the ImmunoID NeXT immunogenomics biomarker discovery platform for biopharma, and CE-IVD marked EDTA and cfDNA blood collection kits. Tests are processed at Personalis' on-site CAP-accredited clinical genomics laboratory in Fremont, California.
Product overview
Personalis offers a platform-plus-modules architecture centered on its NeXT Personal ultrasensitive MRD testing platform for cancer recurrence detection. The core NeXT Personal Dx product uses whole-genome sequencing to detect circulating tumor DNA with sensitivity down to 1 part per million. Supporting the MRD platform are analytics sub-products including GenTraceID (MRD quantification) and VariNTrack (variant tracking), plus the Real-Time Variant Tracker feature for therapy resistance monitoring. The broader portfolio includes NeXT Dx (tissue/liquid biopsy assay), the ImmunoID NeXT immunogenomics platform (encompassing InfiltrateID, ImmunogenomicsID, RepertoireID, and NeoantigenID sub-modules), and CE-IVD marked blood collection kits. The company also provides a CAP-accredited clinical genomics laboratory for test processing.
Differentiator
Problem solved
Functional benefit
Brands
- NeXT Personal Dx: FDA-cleared ultrasensitive MRD test for cancer recurrence detection in blood
- NeXT Personal
- ImmunoID NeXT
- ACE Technology
Products and services
- NeXT Personal Dx An ultrasensitive circulating tumor DNA (ctDNA) test for detecting molecular residual disease (MRD) and cancer recurrence. Uses whole-genome sequencing to track up to ~1,800 patient-specific mutations with sensitivity down to 1 part per million, enabling earlier detection of residual cancer than standard imaging. Sold to oncologists and cancer centers and reimbursed through Medicare for breast cancer, lung cancer, and immunotherapy monitoring indications.
- NeXT Dx A tissue and liquid biopsy assay for solid tumor profiling that provides comprehensive genomic profiling for precision oncology applications. Used by clinicians and biopharma partners for solid tumor characterization.
- ImmunoID NeXT A universal cancer immunogenomics platform providing biomarker assay discovery for immuno-oncology applications. Combines multiple biomarker capabilities including immune cell profiling, tumor microenvironment analysis, and immune repertoire analysis. Sold to biopharma customers for biomarker discovery and immunotherapy research.
- EDTA and cfDNA Blood Collection Kits CE-IVD marked (Class A) blood collection kits for preserving blood sample integrity during collection, transport, and storage for genomic analyses. Designed for use with the NeXT Personal MRD testing platform and distributed to clinical trial sites across the EU and Great Britain.
Quantifiable outcome
- 100% sensitivity for colorectal cancer relapse detection at ASCO 2026
- +5 more outcomes
Companies that use Personalis
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles3 records
Personalis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature5 records
Personalis partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- Tempus AIcoreStrategic commercialization and reference laboratory agreement with Tempus AI to market NeXT Personal across breast cancer, lung cancer, immuno-oncology monitoring, and colorectal cancer indications. Expanded from initial collaboration to target approximately 150,000 colorectal cancer patients annually.
- TRACERx ConsortiumcoreLandmark lung cancer research consortium providing clinical validation data for Medicare coverage. TRACERx study published in Cell demonstrated test's ability to identify residual disease with high accuracy in early-stage non-small cell lung cancer. Podium presentation at ASCO 2026 highlighted single-digit parts-per-million sensitivity.
- AstraZenecacoreCollaboration on Phase 3 LAURA clinical trial demonstrating NeXT Personal MRD test utility in monitoring osimertinib treatment response in unresectable Stage III EGFR-mutated NSCLC. Data presented at ESMO 2025 showing detection of disease progression a median of 5 months ahead of standard imaging.
- Veterans Affairs (VA MVP Program)minorPopulation sequencing contract for the VA Million Veteran Program. New task order of $13.5 million increased total VA MVP contracts to approximately $225 million. Revenue declining as expected wind-down continues.
- University College LondoncoreNEOPRISM-CRC trial collaboration showing 100% sensitivity for disease detection in high-risk colorectal cancer patients. Super molecular responders who cleared ctDNA by second treatment cycle achieved 100% pathological complete response.
- PREDICT-DNA Study Collaboratorscore227 patients across 24 US cancer centers in PREDICT-DNA study published in Journal of Clinical Oncology demonstrating ctDNA monitoring superiority for neoadjuvant therapy response in breast cancer. Supported Medicare coverage for breast cancer neoadjuvant monitoring.
- Vall d'Hebron Institute of OncologyminorClinical evidence provider supporting Medicare coverage for immunotherapy monitoring, demonstrating the test's ultrasensitivity enables ongoing evaluation of treatment response and prediction of clinical outcomes.
- European Union/UK Clinical SitesminorCE Mark approval for EDTA and cfDNA Blood Collection Kits enabling use at clinical trial sites across EU and Great Britain for interventional research under IVDR, expanding market presence in Europe.
Scale indicators12 records
Recent moves6 records
Expansion highlights6 records
Personalis competitors and assessment
Company assessmentDirect peers
- Natera: Direct competitor offering Signatera, a tumor-informed MRD test using a targeted panel approach for cancer recurrence monitoring across multiple solid tumor indications with established Medicare coverage and broad oncologist adoption.
- Guardant Health: Direct competitor in liquid biopsy oncology, offering Guardant360 for tumor profiling and Reveal MRD test; competes with Personalis across clinical genomic profiling and recurrence monitoring in solid tumors.
- Foundation Medicine: Roche subsidiary offering FoundationOne CDx tissue and FoundationOne Liquid CDx for comprehensive genomic profiling of solid tumors; directly overlaps with Personalis's NeXT Dx tissue/liquid biopsy assay.
- Tempus AI: Both a strategic channel partner for NeXT Personal and a direct competitor in oncology molecular profiling and liquid biopsy; offers xT, xR, and xF assays that overlap with Personalis's biopharma and clinical product lines.
- Exact Sciences: Oncology diagnostics company with Cologuard and the Oncotype pipeline; expanding into MRD and liquid biopsy for colorectal and other solid tumor recurrence monitoring, directly adjacent to NeXT Personal's indications.
- NeoGenomics: Specialized oncology testing laboratory offering comprehensive tumor profiling, liquid biopsy, and MRD services (RaDaR); serves both clinicians and biopharma with overlapping use cases to Personalis.
- Caris Life Sciences: Oncology diagnostics company offering MI Profile (tissue) and MI Cancer Seek (blood) for comprehensive molecular profiling and emerging MRD applications; competes in the same biopharma and clinical oncology testing market.
Emerging players
- Foresight Diagnostics: Emerging player in liquid biopsy and MRD with ultrasensitive ctDNA detection technology targeting lymphoma and solid tumor indications; emerging competitive threat to NeXT Personal in the broader MRD market.
- Adaptive Biotechnologies: Clonal sequencing (clonoSEQ) for MRD in hematologic malignancies with established Medicare coverage; serves as both a partial overlap in MRD space and an adjacency in immune profiling, similar to Personalis's ImmunoID NeXT.
Others
- Bio-Techne: Life science tools and diagnostics company whose ExoDx and related oncology reagents serve adjacent biomarker and diagnostic markets; relevant for understanding the broader oncology diagnostics ecosystem in which Personalis operates.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Personalis social profiles
Digital presencePersonalis compliance and trust
Trust signalCompliance2 records
Personalis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Personalis leadership team
Management profileNumber of profiles
Profiles15 records
Personalis funding detail
Funding detailFunding overview
Funding rounds6 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Personalis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Personalis
What does Personalis do?
Personalis fundamentally sells clinical diagnostic testing services and products centered on the NeXT Personal ultrasensitive minimal residual disease (MRD) test, which uses whole-genome sequencing to detect circulating tumor DNA down to ~1 part per million for cancer recurrence detection. The company also offers the NeXT Dx tissue and liquid biopsy assay for solid tumor profiling, the ImmunoID NeXT immunogenomics biomarker discovery platform for biopharma, and CE-IVD marked EDTA and cfDNA blood collection kits. Tests are processed at Personalis' on-site CAP-accredited clinical genomics laboratory in Fremont, California.
Is Personalis a public or private company?
Personalis is a public company. It is classified as public and is currently operating.
When was Personalis founded?
Personalis was founded in 2011. It employs 251 to 500 people.
Where is Personalis based?
Personalis is headquartered in Menlo Park, United States, in the North America region.
How does Personalis make money?
Four revenue lines are on record. Clinical Diagnostic Testing is the primary driver. The others are pharmaceutical Testing Services, VA MVP Program and biopharma Partnerships.
Who are Personalis's main competitors?
Direct peers on record are Natera, Guardant Health, Foundation Medicine, Tempus AI, Exact Sciences, NeoGenomics and Caris Life Sciences. Emerging players are Foresight Diagnostics and Adaptive Biotechnologies. Bio-Techne is listed as an others.
Does Personalis have an API?
No public API is recorded for Personalis.
What industry is Personalis in?
Personalis's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAAANAG, Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing, with a secondary code of HLAAAMAK, Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling). Its NAICS code is 325413 and its SIC code is 2835.